查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401863

2030 年疟疾疫苗市场预测：按药物、疫苗类型、途径、配销通路、最终用户和地区进行的全球分析

Malaria Vaccine Market Forecasts to 2030 - Global Analysis By Agent (Anopheles Species, Plasmodium Vivax, Plasmodium Falciparum and Other Agents), Vaccine Type, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC预测，2023年全球疟疾疫苗市场规模将达541亿美元，预计2030年将达到3,695亿美元，预测期内复合年增长率为31.6%。

疟疾疫苗是针对蚊媒感染疾病提供保护的药物。当被携带疟疾中毒的雌性疟蚊叮咬时，它会传播一种称为疟原虫原虫性疾病的疾病。出汗、发烧和发冷是这种慢性疾病的症状。给药这些疫苗的方法有很多种，包括肌肉注射、皮下注射和皮内注射。

据世界卫生组织称，2019年全球约有2.29亿人感染疟疾，40.9万人死亡。疟疾主要困扰非洲、亚洲、中南美洲等热带地区。

疟疾发病率高

多年来，疟疾一直是主要的健康问题，特别是在热带和亚热带地区。疟疾流行是由多种因素驱动的，包括气候变迁、蚊子和寄生虫的抗药性、卫生基础设施不足以及社会经济因素。然而，由于环境条件的变化和现有预防策略有效性的变化，盛行率有所增加。这些因素都促进了市场的成长。

缺乏医疗基础设施

卫生基础设施不足限制了使用卫生设施的机会，并使疫苗难以取得。在偏远地区，没有诊所或医院来妥善储存和管理疫苗。由于卫生系统不足，健康教育和疫苗接种宣传活动也受到限制。这种知识的缺乏可能会导致疫苗接种率低或对疫苗接种犹豫不决。这是阻碍市场拓展的因素。

增加研发活动

新兴市场疫苗接种成本、安全性和有效性的开拓将影响市场扩张。公共和商业性研究投资影响更新、更强大的疫苗的可用性。此外，政府和国际卫生组织的支持可以对疟疾疫苗的采用和普及产生重大影响，特别是在资源有限的环境中。这些都是影响市场扩张的变数。

药物研发成本高

疫苗开发过程需要大量的财务投资，因为它需要严格的研究、临床试验和监管程序。高製造成本影响大规模生产和分销的可持续性。它也可能阻碍为最需要的人接种疫苗的长期努力。赞助这些配合措施的製药公司、政府和组织面临高昂成本的挑战。

新冠肺炎 (COVID-19) 影响：

医疗用品（特别是预防和治疗疟疾所需的医疗用品）的生产和供应因 COVID-19 造成的全球供应链中断而受到阻碍。这影响了诊断设备、抗疟疾药和散布杀虫剂的蚊帐的供应。封锁、旅行禁令和麵对面咨询的限制都导致疟疾疫苗接种临床研究中断。这导致了测试、观察分析和获得监管部门批准的延迟。

预计按蚊物种部分在预测期内将是最大的

预计按蚊物种部分在预测期内将是最大的。透过接种针对疟蚊的疫苗可以直接解决疟疾传播问题。透过降低蚊子传播疟疾感染的能力，可以显着减缓疟疾传播。针对疟疾寄生虫本身的疫苗接种研究目前正在进行中，而针对按蚊物种的疫苗的开发将有助于此类努力。

预测期内，肌肉注射细分市场的复合年增长率最高。

预计肌肉注射领域在预测期内复合年增长率最高。对于医疗专业人员来说，肌肉注射疫苗是一个相当简单的过程。除了正常的注射程序外，不需要专门的训练。当肌肉注射时，某些疫苗更稳定，可以更好地保持其有效性。这对于冷藏和医疗服务不便的地区常见疾病的疫苗接种尤其重要。

占有率最大的地区

预计北美在预测期内将占据最大的市场占有率。由于这种疾病的广泛影响，世界各地正在配合措施开发和实施疟疾疫苗接种。随着北美大陆风险的下降，该地区不再关注全民免疫，而是更关注对疟疾高发地区的人们进行预防。对于前往疟疾流行地区的人来说，重要的预防措施是避免蚊虫叮咬并使用抗疟疾药。

复合年增长率最高的地区：

由于疟疾病例数量增加、人口成长以及政府控制疾病的配合措施加大，预计亚太地区在预测期内将维持最高的复合年增长率。学术机构、製药公司和国际卫生组织正在不懈地努力开发更有效的疟疾疫苗。也正在进行研究，重点在于针对疟疾寄生虫生命週期不同阶段的替代疫苗接种策略，以提高功效。

免费客製化服务

订阅此报告的客户可以利用以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球疟疾疫苗市场：依药物分类

  • 介绍
  • 按蚊种
  • 间日疟原虫
  • 恶性疟原虫
  • 其他的

第六章全球疟疾疫苗市场：依疫苗类型

  • 介绍
  • 红血球前疫苗
  • 红血球疫苗
  • 多重抗原疫苗
  • 其他类型的疫苗

第七章全球疟疾疫苗市场：依给药途径分类

  • 介绍
  • 肌肉注射
  • 皮下的
  • 皮内

第八章全球疟疾疫苗市场：依配销通路

  • 介绍
  • 零售药房
  • 线上药房
  • 医院药房
  • 其他配销通路

第九章全球疟疾疫苗市场：依最终用户分类

  • 介绍
  • 医院
  • 专科诊所
  • 居家医疗
  • 其他最终用户

第十章全球疟疾疫苗市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • Taj Pharmaceuticals Limited
  • Sanofi
  • Actiza Pharmaceutical Private Limited
  • Ipca Laboratories Ltd.
  • Sumaya Biotech
  • Hikma Pharmaceuticals PLC
  • Bliss GVS Pharma Ltd.
  • Amneal Pharmaceuticals LLC
  • Strides Pharma Science Limited
  • VLP Therapeutics
  • Novartis AG
  • Pfizer Inc.
  • Mylan NV
  • Zydus Cadila
  • Cipla Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Ipca Laboratories Ltd.
  • GeoVax
Product Code: SMRC24383

According to Stratistics MRC, the Global Malaria Vaccine Market is accounted for $54.1 billion in 2023 and is expected to reach $369.5 billion by 2030 growing at a CAGR of 31.6% during the forecast period. Vaccines against malaria are medicines that offer protection against the infectious sickness carried by mosquitoes. The bite of a female Anopheles mosquito carrying the malaria virus transmits the disease, sometimes referred to as plasmodium infection. Sweating, fever, and chills are signs of this chronic illness. There are a few different ways to administer these vaccines: intramuscular, subcutaneous, and intradermal injections.

According to the WHO, there were around 229 million malaria infections and 409,000 fatalities worldwide in 2019. Malaria has primarily plagued tropical areas such as Africa, Asia, Central America, and South America.

Market Dynamics:

Driver:

High Incidence of malaria

Malaria has been a significant health concern for many years, particularly in tropical and subtropical regions. Several factors contribute to the prevalence of malaria, including climate change, drug resistance in mosquitoes and parasites, inadequate healthcare infrastructure, and socioeconomic factors. However, the rise in prevalence occurs due to changing environmental conditions or shifts in the effectiveness of existing prevention strategies. These factors contribute to the growth of the market.

Restraint:

Lack of healthcare infrastructure

People find it challenging to obtain vaccines due to restricted access to healthcare facilities resulting from inadequate infrastructure for healthcare. There aren't any clinics or hospitals in remote locations that are set up to properly store and give immunizations. Inadequate healthcare systems may also result in restricted availability of health education and immunization awareness initiatives. Low vaccination uptake and vaccine hesitancy may result from this lack of knowledge. This is the element impeding the market's expansion.

Opportunity:

Increase in the number of research and development activities

Developments in vaccination cost, safety, and effectiveness have an impact on market expansion. Public and commercial research investments have an impact on the availability of more recent and potent vaccinations. Furthermore, particularly in environments with limited resources, government and international health agency support can have a major influence on the uptake and dissemination of malaria vaccinations. These are the variables affecting the market's expansion.

Threat:

High cost of medication development

The process of developing a vaccine necessitates significant financial investments due to the rigorous research, clinical trials, and regulatory procedures involved. The sustainability of mass production and distribution is impacted if the cost of manufacturing is high. Long-term efforts to get the vaccination to people who need it most could be hampered by it. Pharmaceutical firms, governments, and organizations that sponsor these initiatives have difficulties because to the exorbitant expenses.

COVID-19 Impact:

The manufacture and delivery of medical goods, especially those required for the prevention and treatment of malaria, were hampered by the worldwide interruptions in supply chains brought about by COVID-19. This impacted the supply of diagnostic instruments, antimalarial medications, and bed nets sprayed with insecticide. Lockdowns, travel bans, and limits on face-to-face encounters all caused interruptions to clinical studies for malaria vaccinations. As a result, there has been a delay in testing, findings analysis, and gaining regulatory permissions.

The anopheles species segment is expected to be the largest during the forecast period

The anopheles species segment is expected to be the largest during the forecast period. The transmission of malaria is directly addressed by vaccination against the anopheles species. It may considerably slow the transmission of malaria by lessening the mosquito's capacity to disseminate the infection. Research on vaccinations against the malaria parasite itself is ongoing, however these efforts would be aided by the development of a vaccine against the anopheles species.

The intramuscular segment is expected to have the highest CAGR during the forecast period

The intramuscular segment is expected to have the highest CAGR during the forecast period. For medical experts, administering a vaccination intramuscularly is a rather simple process. Specialized training beyond normal injection procedures is not needed. When injected intramuscularly, certain vaccinations are more stable and maintain their effectiveness more effectively. This is particularly important for vaccinations against illnesses that are common in areas without easy access to refrigeration or healthcare services.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Due of the disease's extensive effects, efforts have been made globally to develop and implement malaria vaccinations. Because of the decreased risk within the continent, the focus in this region has mostly been on preventive methods for visitors to malaria-prone regions rather than universal immunization. The key tactics for people visiting areas where malaria is endemic continue to be preventing mosquito bites and using antimalarial drugs.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to the increasing number of malarial infections, rising population and increasing government initiative for disease control. To create more potent malaria vaccines, academic institutions, pharmaceutical firms, and international health organizations have been working nonstop. In an effort to increase effectiveness, some ongoing research focuses on alternate vaccination strategies that target various phases of the malaria parasite's lifecycle.

Key players in the market:

Some of the key players in Malaria Vaccine market include Taj Pharmaceuticals Limited, Sanofi, Actiza Pharmaceutical Private Limited, Ipca Laboratories Ltd., Sumaya Biotech, Hikma Pharmaceuticals PLC, Bliss GVS Pharma Ltd., Amneal Pharmaceuticals LLC, Strides Pharma Science Limited, VLP Therapeutics, Novartis AG, Pfizer Inc., Mylan N.V., Zydus Cadila, Cipla Inc., Sun Pharmaceutical Industries Ltd., Ipca Laboratories Ltd. and GeoVax.

Key Developments:

In February 2023, Sun Pharmaceutical Industries Ltd., one of India's leading pharmaceutical companies, has announced the acquisition of a 26.09% stake in Agatsa Software Pvt. Ltd. and a 27.39% stake in Remidio Innovative Solutions Pvt. Ltd., both of which are digital health startups.

In November 2022, Novartis and Medicines for Malaria Venture (MMV) have announced plans to advance a ganaplacide/lumefantrine- solid dispersion formulation (SDF) into a Phase III clinical trial to treat individuals with acute uncomplicated malaria caused by Plasmodium falciparum.

Agents Covered:

  • Anopheles Species
  • Plasmodium Vivax
  • Plasmodium Falciparum
  • Other Agents

Vaccine Types Covered:

  • Pre-Erythrocytic Vaccine
  • Erythrocytic Vaccine
  • Multi-antigen Vaccine
  • Other Vaccine Types

Route of Administrations Covered:

  • Intramuscular
  • Subcutaneous
  • Intradermal

Distribution Channels Covered:

  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
  • Other Distribution Channels

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Malaria Vaccine Market, By Agent

  • 5.1 Introduction
  • 5.2 Anopheles Species
  • 5.3 Plasmodium Vivax
  • 5.4 Plasmodium Falciparum
  • 5.5 Other Agents

6 Global Malaria Vaccine Market, By Vaccine Type

  • 6.1 Introduction
  • 6.2 Pre-Erythrocytic Vaccine
  • 6.3 Erythrocytic Vaccine
  • 6.4 Multi-antigen Vaccine
  • 6.5 Other Vaccine Types

7 Global Malaria Vaccine Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Intramuscular
  • 7.3 Subcutaneous
  • 7.4 Intradermal

8 Global Malaria Vaccine Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Retail Pharmacy
  • 8.3 Online Pharmacy
  • 8.4 Hospital Pharmacy
  • 8.5 Other Distribution Channels

9 Global Malaria Vaccine Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Specialty Clinics
  • 9.4 Homecare
  • 9.5 Other End Users

10 Global Malaria Vaccine Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Taj Pharmaceuticals Limited
  • 12.2 Sanofi
  • 12.3 Actiza Pharmaceutical Private Limited
  • 12.4 Ipca Laboratories Ltd.
  • 12.5 Sumaya Biotech
  • 12.6 Hikma Pharmaceuticals PLC
  • 12.7 Bliss GVS Pharma Ltd.
  • 12.8 Amneal Pharmaceuticals LLC
  • 12.9 Strides Pharma Science Limited
  • 12.10 VLP Therapeutics
  • 12.11 Novartis AG
  • 12.12 Pfizer Inc.
  • 12.13 Mylan N.V.
  • 12.14 Zydus Cadila
  • 12.15 Cipla Inc.
  • 12.16 Sun Pharmaceutical Industries Ltd.
  • 12.17 Ipca Laboratories Ltd.
  • 12.18 GeoVax

List of Tables

  • Table 1 Global Malaria Vaccine Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Malaria Vaccine Market Outlook, By Agent (2021-2030) ($MN)
  • Table 3 Global Malaria Vaccine Market Outlook, By Anopheles Species (2021-2030) ($MN)
  • Table 4 Global Malaria Vaccine Market Outlook, By Plasmodium Vivax (2021-2030) ($MN)
  • Table 5 Global Malaria Vaccine Market Outlook, By Plasmodium Falciparum (2021-2030) ($MN)
  • Table 6 Global Malaria Vaccine Market Outlook, By Other Agents (2021-2030) ($MN)
  • Table 7 Global Malaria Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 8 Global Malaria Vaccine Market Outlook, By Pre-Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 9 Global Malaria Vaccine Market Outlook, By Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 10 Global Malaria Vaccine Market Outlook, By Multi-antigen Vaccine (2021-2030) ($MN)
  • Table 11 Global Malaria Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
  • Table 12 Global Malaria Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 12 Global Malaria Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 14 Global Malaria Vaccine Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 15 Global Malaria Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
  • Table 16 Global Malaria Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 17 Global Malaria Vaccine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 18 Global Malaria Vaccine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 19 Global Malaria Vaccine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 20 Global Malaria Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 21 Global Malaria Vaccine Market Outlook, By End User (2021-2030) ($MN)
  • Table 22 Global Malaria Vaccine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 23 Global Malaria Vaccine Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 24 Global Malaria Vaccine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 25 Global Malaria Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 26 North America Malaria Vaccine Market Outlook, By Country (2021-2030) ($MN)
  • Table 27 North America Malaria Vaccine Market Outlook, By Agent (2021-2030) ($MN)
  • Table 28 North America Malaria Vaccine Market Outlook, By Anopheles Species (2021-2030) ($MN)
  • Table 29 North America Malaria Vaccine Market Outlook, By Plasmodium Vivax (2021-2030) ($MN)
  • Table 30 North America Malaria Vaccine Market Outlook, By Plasmodium Falciparum (2021-2030) ($MN)
  • Table 31 North America Malaria Vaccine Market Outlook, By Other Agents (2021-2030) ($MN)
  • Table 32 North America Malaria Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 33 North America Malaria Vaccine Market Outlook, By Pre-Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 34 North America Malaria Vaccine Market Outlook, By Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 35 North America Malaria Vaccine Market Outlook, By Multi-antigen Vaccine (2021-2030) ($MN)
  • Table 36 North America Malaria Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
  • Table 37 North America Malaria Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 38 North America Malaria Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 39 North America Malaria Vaccine Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 40 North America Malaria Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
  • Table 41 North America Malaria Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 42 North America Malaria Vaccine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 43 North America Malaria Vaccine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 44 North America Malaria Vaccine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 45 North America Malaria Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 46 North America Malaria Vaccine Market Outlook, By End User (2021-2030) ($MN)
  • Table 47 North America Malaria Vaccine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 48 North America Malaria Vaccine Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 49 North America Malaria Vaccine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 50 North America Malaria Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 51 Europe Malaria Vaccine Market Outlook, By Country (2021-2030) ($MN)
  • Table 52 Europe Malaria Vaccine Market Outlook, By Agent (2021-2030) ($MN)
  • Table 53 Europe Malaria Vaccine Market Outlook, By Anopheles Species (2021-2030) ($MN)
  • Table 54 Europe Malaria Vaccine Market Outlook, By Plasmodium Vivax (2021-2030) ($MN)
  • Table 55 Europe Malaria Vaccine Market Outlook, By Plasmodium Falciparum (2021-2030) ($MN)
  • Table 56 Europe Malaria Vaccine Market Outlook, By Other Agents (2021-2030) ($MN)
  • Table 57 Europe Malaria Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 58 Europe Malaria Vaccine Market Outlook, By Pre-Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 59 Europe Malaria Vaccine Market Outlook, By Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 60 Europe Malaria Vaccine Market Outlook, By Multi-antigen Vaccine (2021-2030) ($MN)
  • Table 61 Europe Malaria Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
  • Table 62 Europe Malaria Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 63 Europe Malaria Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 64 Europe Malaria Vaccine Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 65 Europe Malaria Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
  • Table 66 Europe Malaria Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 67 Europe Malaria Vaccine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 68 Europe Malaria Vaccine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 69 Europe Malaria Vaccine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 70 Europe Malaria Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 71 Europe Malaria Vaccine Market Outlook, By End User (2021-2030) ($MN)
  • Table 72 Europe Malaria Vaccine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 73 Europe Malaria Vaccine Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 74 Europe Malaria Vaccine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 75 Europe Malaria Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 76 Asia Pacific Malaria Vaccine Market Outlook, By Country (2021-2030) ($MN)
  • Table 77 Asia Pacific Malaria Vaccine Market Outlook, By Agent (2021-2030) ($MN)
  • Table 78 Asia Pacific Malaria Vaccine Market Outlook, By Anopheles Species (2021-2030) ($MN)
  • Table 79 Asia Pacific Malaria Vaccine Market Outlook, By Plasmodium Vivax (2021-2030) ($MN)
  • Table 80 Asia Pacific Malaria Vaccine Market Outlook, By Plasmodium Falciparum (2021-2030) ($MN)
  • Table 81 Asia Pacific Malaria Vaccine Market Outlook, By Other Agents (2021-2030) ($MN)
  • Table 82 Asia Pacific Malaria Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 83 Asia Pacific Malaria Vaccine Market Outlook, By Pre-Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 84 Asia Pacific Malaria Vaccine Market Outlook, By Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 85 Asia Pacific Malaria Vaccine Market Outlook, By Multi-antigen Vaccine (2021-2030) ($MN)
  • Table 86 Asia Pacific Malaria Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
  • Table 87 Asia Pacific Malaria Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 88 Asia Pacific Malaria Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 89 Asia Pacific Malaria Vaccine Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 90 Asia Pacific Malaria Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
  • Table 91 Asia Pacific Malaria Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 92 Asia Pacific Malaria Vaccine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 93 Asia Pacific Malaria Vaccine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 94 Asia Pacific Malaria Vaccine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 95 Asia Pacific Malaria Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 96 Asia Pacific Malaria Vaccine Market Outlook, By End User (2021-2030) ($MN)
  • Table 97 Asia Pacific Malaria Vaccine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 98 Asia Pacific Malaria Vaccine Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 99 Asia Pacific Malaria Vaccine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 100 Asia Pacific Malaria Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 101 South America Malaria Vaccine Market Outlook, By Country (2021-2030) ($MN)
  • Table 102 South America Malaria Vaccine Market Outlook, By Agent (2021-2030) ($MN)
  • Table 103 South America Malaria Vaccine Market Outlook, By Anopheles Species (2021-2030) ($MN)
  • Table 104 South America Malaria Vaccine Market Outlook, By Plasmodium Vivax (2021-2030) ($MN)
  • Table 105 South America Malaria Vaccine Market Outlook, By Plasmodium Falciparum (2021-2030) ($MN)
  • Table 106 South America Malaria Vaccine Market Outlook, By Other Agents (2021-2030) ($MN)
  • Table 107 South America Malaria Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 108 South America Malaria Vaccine Market Outlook, By Pre-Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 109 South America Malaria Vaccine Market Outlook, By Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 110 South America Malaria Vaccine Market Outlook, By Multi-antigen Vaccine (2021-2030) ($MN)
  • Table 111 South America Malaria Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
  • Table 112 South America Malaria Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 113 South America Malaria Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 114 South America Malaria Vaccine Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 115 South America Malaria Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
  • Table 116 South America Malaria Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 117 South America Malaria Vaccine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 118 South America Malaria Vaccine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 119 South America Malaria Vaccine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 120 South America Malaria Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 121 South America Malaria Vaccine Market Outlook, By End User (2021-2030) ($MN)
  • Table 122 South America Malaria Vaccine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 123 South America Malaria Vaccine Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 124 South America Malaria Vaccine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 125 South America Malaria Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 126 Middle East & Africa Malaria Vaccine Market Outlook, By Country (2021-2030) ($MN)
  • Table 127 Middle East & Africa Malaria Vaccine Market Outlook, By Agent (2021-2030) ($MN)
  • Table 128 Middle East & Africa Malaria Vaccine Market Outlook, By Anopheles Species (2021-2030) ($MN)
  • Table 129 Middle East & Africa Malaria Vaccine Market Outlook, By Plasmodium Vivax (2021-2030) ($MN)
  • Table 130 Middle East & Africa Malaria Vaccine Market Outlook, By Plasmodium Falciparum (2021-2030) ($MN)
  • Table 131 Middle East & Africa Malaria Vaccine Market Outlook, By Other Agents (2021-2030) ($MN)
  • Table 132 Middle East & Africa Malaria Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 133 Middle East & Africa Malaria Vaccine Market Outlook, By Pre-Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 134 Middle East & Africa Malaria Vaccine Market Outlook, By Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 135 Middle East & Africa Malaria Vaccine Market Outlook, By Multi-antigen Vaccine (2021-2030) ($MN)
  • Table 136 Middle East & Africa Malaria Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
  • Table 137 Middle East & Africa Malaria Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 138 Middle East & Africa Malaria Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 139 Middle East & Africa Malaria Vaccine Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 140 Middle East & Africa Malaria Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
  • Table 141 Middle East & Africa Malaria Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 142 Middle East & Africa Malaria Vaccine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 143 Middle East & Africa Malaria Vaccine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 144 Middle East & Africa Malaria Vaccine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 145 Middle East & Africa Malaria Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 146 Middle East & Africa Malaria Vaccine Market Outlook, By End User (2021-2030) ($MN)
  • Table 147 Middle East & Africa Malaria Vaccine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 148 Middle East & Africa Malaria Vaccine Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 149 Middle East & Africa Malaria Vaccine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 150 Middle East & Africa Malaria Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)